Tirzepatide | Peptide Encyclopedia | Auryx
Tirzepatide is a physician-reviewed Auryx Learn encyclopedia entry. A dual GLP-1 and GIP receptor agonist researched for its effects on metabolic and glycemic parameters beyond GLP-1 monotherapy. This page is educational. It is not a dosing guide and not a substitute for a licensed clinician.
How it works
Tirzepatide acts on both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. GIP activation adds a distinct anabolic fat-storage inhibition pathway on top of GLP-1's appetite suppression, producing greater fat mass reduction than single-agonist protocols in clinical trials.
- Greater average fat loss vs. semaglutide in head-to-head trials
- Superior HbA1c reduction
- Preservation of lean muscle mass during weight loss
- Improved lipid panel and blood pressure
Preferred for individuals who need aggressive fat loss or who have not achieved goals with GLP-1 monotherapy.
Investigated in multiple large-scale clinical trials as a dual GLP-1/GIP receptor agonist. Phase 3 data demonstrates significant differential effects compared to GLP-1 monotherapy.
Clinic context and next steps
Pair this entry with the matching shop listing when Auryx offers the compound, or browse the full encyclopedia. Category shopping lives under shop. Mechanism language is not a personal outcome and does not approve a protocol.
Auryx is an MD-led telemedicine clinic. Eligible patients complete remote intake; compounds ship from regulated United States compounding pharmacies after clinical review. Use the protocol finder if you are matching a goal, our method for the four-step process, and about for physician leadership. Citations sit on sources. Questions go to contact or info@auryxlife.com.
Nothing on Learn diagnoses, treats, cures, or prevents disease. Read privacy and terms before you share health information. Language homepages: español and português.